(BCAT) BlackRock Capital - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US09260U1097

BCAT: Mutual Funds, Portfolio Management, Custody Services

BlackRock Capital Allocation Trust (NYSE:BCAT) is a closed-end investment management vehicle managed by BlackRock, a leading global asset management firm. As a specialist in asset management, BCAT is designed to provide investors with a diversified portfolio and a steady income stream.

BCATs investment strategy focuses on allocating capital across various asset classes, aiming to balance risk and returns. The trusts portfolio is likely to comprise a mix of equities, fixed income securities, and alternative investments, leveraging BlackRocks expertise in navigating complex markets.

From a technical standpoint, BCATs recent price action indicates a relatively stable trend, with the stock trading above its 20-day, 50-day, and 200-day simple moving averages (SMA20, SMA50, and SMA200). The Average True Range (ATR) suggests moderate volatility, with a recent price of $14.83 and an ATR of 0.32, representing 2.13% of the current price. Given the current technical setup, we can expect BCAT to continue its upward trajectory, potentially targeting the 52-week high of $14.99.

Fundamentally, BCATs market capitalization stands at $1.499 billion, with a price-to-earnings (P/E) ratio of 7.82, indicating a relatively attractive valuation compared to its earnings. The trusts return on equity (RoE) is 10.60%, suggesting a decent level of profitability. Considering the current fundamental data and technical trends, we forecast that BCAT will continue to perform steadily, driven by BlackRocks expertise and the trusts diversified portfolio. Our forecast suggests a potential price target of $16.20 within the next 12 months, based on a combination of technical and fundamental analysis.

To achieve this forecast, BCAT will need to maintain its current investment strategy, continue to benefit from BlackRocks asset management capabilities, and navigate the prevailing market conditions effectively. Any significant changes in market sentiment, interest rates, or the overall economic landscape could impact BCATs performance, and investors should closely monitor these factors.

Additional Sources for BCAT Stock

BCAT Stock Overview

Market Cap in USD 1,592m
Sector Financial Services
Industry Asset Management
GiC Sub-Industry Asset Management & Custody Banks
IPO / Inception 2020-09-25

BCAT Stock Ratings

Growth Rating 27.0
Fundamental -
Dividend Rating 94.5
Rel. Strength -6.12
Analysts -
Fair Price Momentum 19.50 USD
Fair Price DCF 60.16 USD

BCAT Dividends

Dividend Yield 12m 23.82%
Yield on Cost 5y 28.53%
Annual Growth 5y 91.11%
Payout Consistency 82.5%

BCAT Growth Ratios

Growth Correlation 3m -5.9%
Growth Correlation 12m 58.4%
Growth Correlation 5y 23.1%
CAGR 5y 4.57%
CAGR/Max DD 5y 0.13
Sharpe Ratio 12m 0.68
Alpha 7.61
Beta 0.499
Volatility 14.70%
Current Volume 552.2k
Average Volume 20d 425.6k
What is the price of BCAT stocks?
As of May 17, 2025, the stock is trading at USD 14.84 with a total of 552,239 shares traded.
Over the past week, the price has changed by +1.95%, over one month by +10.27%, over three months by +1.15% and over the past year by +16.61%.
Is BlackRock Capital a good stock to buy?
Neither. Based on ValueRay Analyses, BlackRock Capital is currently (May 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 26.95 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BCAT as of May 2025 is 19.50. This means that BCAT is currently undervalued and has a potential upside of +31.4% (Margin of Safety).
Is BCAT a buy, sell or hold?
BlackRock Capital has no consensus analysts rating.
What are the forecast for BCAT stock price target?
According to ValueRays Forecast Model, BCAT BlackRock Capital will be worth about 21.8 in May 2026. The stock is currently trading at 14.84. This means that the stock has a potential upside of +47.04%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 21.8 47%